ArticleVirulence2015
Looking into Candida albicans infection, host response, and antifungal strategies.
Article in Virulence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.Journal of hepatology · 2020Trial
- Metabolomic profiling reveals alterations in Candida pathophysiology and host interactions during primary oral candidiasis and following antifungal treatment.Scientific reports · 2026Article
- Chelerythrine enhances anti-fungi immunity inFrontiers in immunology · 2026Article
- The pathogenicity and future treatment strategies ofFrontiers in cellular and infection microbiology · 2026Review
- Evaluation and testing of polymethylmetacrylic (PMMA) bone cements with admixed Amphotericin B.Journal of orthopaedic surgery and research · 2025Article
- The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications.Molecular cancer · 2025Review
- Article
- Activity of thonningianin A against Candida albicans in vitro and in vivo.Applied microbiology and biotechnology · 2024Article
- Activity of propolis from Mexico on the proliferation and virulence factors of Candida albicans.BMC microbiology · 2023Article
- In silico identification of 1,2,4-triazoles as potential Candida Albicans inhibitors using 3D-QSAR, molecular docking, molecular dynamics simulations, and ADMET profiling.Molecular diversity · 2023Article
- An Insight into In Vitro Antioxidant, Antimicrobial, Cytotoxic, and Apoptosis Induction Potential of Mangiferin, a Bioactive Compound Derived fromPlants (Basel, Switzerland) · 2023Article
- Calcitermin-Loaded Smart Gels Activity againstGels (Basel, Switzerland) · 2023Article
- Ssa1-targeted antibody prevents host invasion byFrontiers in microbiology · 2023Article
- Targeting Virulence Factors ofFoods (Basel, Switzerland) · 2022Review
- Cross-kingdom interaction betweenFrontiers in microbiology · 2022Review
- The prophylactic effects of monoclonal antibodies targeting the cell wall Pmt4 protein epitopes ofFrontiers in microbiology · 2022Article
- Mangiferin enhances the antifungal activities of caspofungin by destroying polyamine accumulation.Virulence · 2021Article
- The effects of secreted aspartyl proteinase inhibitor ritonavir on azoles-resistant strains of Candida albicans as well as regulatory role of SAP2 and ERG11.Immunity, inflammation and disease · 2021Article
- Article
- Anti-Fungal Efficacy and Mechanisms of Flavonoids.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans, a commonly encountered fungal pathogen, causes diseases varying from superficial mucosal complaints to life-threatening systemic disorders. Among the virulence traits of C. albicans, yeast-to-hypha transition is most widely acknowledged. Host innate immunity to C. albicans critically requires pattern recognition receptors (PRRs), and defence against C. albicans infection is provided by an exquisite interplay between the innate and adaptive arms of the host immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.